Nvidia and Eli Lilly Launch $1B AI Lab to Accelerate Drug Discovery

Nvidia and Eli Lilly have announced the creation of a pioneering joint innovation lab focused on applying artificial intelligence to address some of the challenges in the pharmaceutical industry.

The lab combines Lilly’s leading expertise in drug discovery, development, and manufacturing with Nvidia’s leadership in artificial intelligence, accelerated computing, and infrastructure. The two companies will jointly invest up to $1 billion in talent, infrastructure, and computing power over the next five years to create this innovation lab.

NVIDIA and Eli Lilly Launch $1B AI Lab to Accelerate Drug Discovery

The center will be based in the San Francisco Bay Area. The lab will bring together Lilly experts in Biology, Science and Medicine alongside engineers and AI model developers from Nvidia, who will work together to generate large-scale data and develop advanced artificial intelligence models capable of accelerating drug development, using Nvidia BioNeMo as a key platform.

“Artificial intelligence is transforming every sector, and its most profound impact will be in the life sciences,” said Jensen Huang, founder and CEO of Nvidia. Both companies “are combining the best of their respective industries to create a new model for drug development, in which scientists can explore biological and chemical spaces in silico before synthesizing a single molecule.”

“For nearly 150 years, we have been working to bring life-changing medicines to patients,” said David A. Ricks, president and CEO of Lilly. “Combining our vast data and scientific expertise with Nvidia’s computing power and modeling experience could transform drug discovery and development as we know it. By bringing together world-class talent in a startup-like environment, we are creating the conditions for innovations that neither company could achieve on its own.”

The collaboration will initially focus on creating a continuous learning system that closely connects Lilly’s agent-enabled wet labs with dry labs, enabling 24/7 AI-assisted experimentation to support the work of biologists and chemists. This approach, with the scientist at the heart of the process, aims to ensure that experiments, data generation, and AI model development are constantly improving and providing feedback to each other.

With the generation of large volumes of high-quality data and the use of NVIDIA BioNeMo as a platform to accelerate drug discovery, the teams will focus on developing next-generation foundational and frontier models for biology and chemistry.

This initiative expands Lilly’s previously announced AI supercomputer and leverages investments in Nvidia’s next-generation architectures, including Nvidia Vera Rubin. Lilly’s AI factory, announced last fall and the most powerful in the pharmaceutical industry, will train large, foundational biomedical models to identify, optimize, and validate new molecules with exceptional speed and accuracy.

It will also support new and advanced applications in manufacturing, medical imaging, and AI-powered scientific agents

Beyond drug discovery, the initiative will explore opportunities to apply artificial intelligence in clinical development, manufacturing, and commercial operations, integrating multimodal models, agentive AI, robotics, and digital twins.

The use of physical artificial intelligence and robotics in the AI ​​factory will also allow Lilly to expand its manufacturing capacity for high-demand medicines and strengthen the reliability of the supply chain.

“Lilly will be able to create digital twins of its production lines to model, stress-test and optimize entire supply chains before making physical changes in the real environment,” the company said.

__

(Featured image by Raimond Klavins via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in diariofarma. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.